14 03, 2023

MV140 Vaccine for Recurrent Urinary Tract Infections in the News

The Globe and Mail and CTV News recently published reports indicating that MV140, Red Leaf Medical’s sublingual vaccine for the prevention of recurrent urinary tract infections in women, is awaiting Health Canada approval. The news items explain the impact of UTIs on women’s health and how the antibiotics used to treat them are contributing to antimicrobial resistance. Read the online CTV story here and watch the video of the story that aired on their broadcast here. The Globe and Mail article was published on February 27, 2023.

28 03, 2022

Red Leaf Medical Files for Approval of UROMUNE™ in Canada

Red Leaf Medical has filed a new drug submission with Health Canada for approval of UROMUNE™, a sublingual vaccine for the prevention of recurrent urinary tract infections(rUTIs) in women. The new drug submission is supported by results from a UROMUNE™ multicenter, prospective, randomized, double-blind, placebo-controlled trial. These results were recently published in the New England Journal of Medicine Evidence.

30 12, 2020

RLM Expands Licensing Agreement with Inmunotek

Through an exclusive licensing agreement, RLM is preparing to bring new vaccines to Canada to prevent recurrent urinary tract infections and recurrent respiratory tract infections. The agreement includes BACTEK™ and UROMUNE™, novel sublingual vaccines.

Go to Top